Research
Clinical Research
Cissuslean® has been evaluated in two randomized, double-blind, placebo-controlled human clinical trials — in overweight or obese adults and in adults diagnosed with knee osteoarthritis. Manuscripts for both completed studies are currently in preparation.
Cissuslean® for Weight & Body-Fat Management
Design
12-week, randomized, double-blind, placebo-controlled, parallel-group
Participants
100 randomized (50 active + 50 placebo); PPS 45 + 41
Primary endpoint
Change in body fat mass (DEXA)
Key results
Waist circumference
Cissuslean®: 90.39 → 88.61 cm
Placebo: 91.75 → 92.66 cm
p = 0.0024
Hip circumference
Cissuslean®: 105.25 → 103.01 cm
Placebo: 106.61 → 107.63 cm
p = 0.0002
Visceral fat area
Cissuslean®: 74.92 → 68.59 cm²
Placebo: 77.23 → 75.53 cm²
p = 0.0001
Subcutaneous fat area
Cissuslean®: 240.24 → 235.67 cm²
Placebo: 249.17 → 250.03 cm²
p = 0.0225
Favorable changes were also reported in total cholesterol, LDL, triglycerides, VLDL and HDL. Adiponectin increased while leptin declined more substantially than placebo. Cissuslean® was well tolerated with no serious adverse events or clinically significant laboratory abnormalities.
Cissuslean® for Knee Osteoarthritis
Design
Prospective, randomized, double-blind, placebo-controlled
Participants
100 randomized; PPS 48 + 45
Dose · Duration
300 mg/day · 84 days
Key results at 300 mg/day
−45.66%
Total WOMAC score (vs −3.57% placebo, p<0.001)
−21.29%
VAS pain (vs −1.37% placebo, p<0.001)
−44.96%
WOMAC pain (vs −3.93% placebo)
−34.44%
Stiffness (vs −5.13% placebo)
−48.01%
Difficulty with daily activities (vs −3.16% placebo)
↓
IL-6, MMP-3, LTB4 and hs-CRP relative to placebo
Clinical Evidence Summary
| Study | Design | N | Dose | Duration | Primary findings |
|---|---|---|---|---|---|
| Weight & body-fat trial | RDBPC | 100 | Not stated | 12 weeks | Reduced body fat and waist, hip, visceral-fat measures |
| Knee osteoarthritis trial | RDBPC | 100 | 300 mg/day | 84 days | 45.66% reduction in WOMAC; 21.29% reduction in VAS pain |
Clinical findings are based on company-supplied study presentations. Human trial manuscripts had not yet been published in a peer-reviewed journal at the time this page was prepared.